Alba A. Brandes - Concepedia

Author

Alba A. Brandes

Istituti di Ricovero e Cura a Carattere Scientifico ORCID

Also Known As

A A Brandes, A BRANDES, A Brandes, A. A. BRANDES, A. A. Brandes, A. Brandes, A.A Brandes, A.A. Brandes, ALBA A BRANDES, Agostino Baruzzi

648

Publications

62.3K

Citations

H-Index

114

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico European Organisation for Research and Treatment of Cancer Institute of Neurological Sciences Azienda USL di Bologna University of Padua

About

Alba A. Brandes is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	93	16.7K
2	Health Sciences	23	38	3K
3	Nursing	3	3	129
4	Education	1	1	16
5	Engineering	1	1	20

Alba A. Brandes

191

Publications

55.3K

Citations

H-Index

Page 1

	Year	Citations
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma Roger Stupp, Warren Mason, Martin J. van den Bent, New England Journal of Medicine	2005	21K
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Roger Stupp, Monika E. Hegi, Warren Mason, The Lancet Oncology 5-Year AnalysisNeuro-oncologyOncologyRadiation TherapyAdjuvant Temozolomide	2009	7.7K
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma Olivier Chinot, Wolfgang Wick, Warren Mason, New England Journal of Medicine	2014	2.4K
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma David A. Reardon, Alba A. Brandes, Antonio Omuro, JAMA Oncology	2020	1.4K
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951 Martin J. van den Bent, Alba A. Brandes, Martin Taphoorn, Journal of Clinical Oncology	2012	1.2K
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma James Perry, Normand Laperrière, Christopher J. O’Callaghan, New England Journal of Medicine	2017	1.1K
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial Michael Weller, Nicholas Butowski, David Tran, The Lancet Oncology Egfrviii-expressing GlioblastomaNeuro-oncologyAct IvGliomaInternational Phase 3	2017	1.1K
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial Roger Stupp, Monika E. Hegi, Thierry Gorlia, The Lancet Oncology Neuro-oncologyGliomaMedicineStandard TreatmentPathology	2014	1K
Lomustine and Bevacizumab in Progressive Glioblastoma Wolfgang Wick, Thierry Gorlia, Martin Bendszus, New England Journal of Medicine	2017	949
<i>MGMT</i> Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients Alba A. Brandes, Enrico Franceschi, Alicia Tosoni, Journal of Clinical Oncology	2008	819

Page 1